24.03.29 () 21:17

Dailypharm

X
'' ӻ غ
Ȱ 2021-06-24 06:00:52
'' ӻ غ
Ȱ 2021-06-24 06:00:52
[ȱ ̿] 'ASCO 2021' -1

Ϻ ϼ öáȫ



߹ : ȱ ̿
߱ȹ : Ȱ
Կ :
⿬: Ϻ ϼ öáȫ


Ȱ: û , ȳϼ. ϸ Ȱ Դϴ. 6 Ƿ м簡 ϴ. 4Ϻ 8ϱ ׾Ͽ о ְ ް ִ ̱ӻȸ(ASCO 2021) мȸ ֵǸ鼭 ߰ſ ޾ҽϴ. ڷγ̷ (ڷγ19) ķ 2 Ǹ鼭 ƽ ϴ.

׷ ̷ ƽ ޷ Ư ð ߽ϴ. Ϻ ϼ  ð ASCO 2021 ٽ ¤ٵ. ö, ȫ, ҰҲ.

öáȫ: ȳϼ, ݰϴ.

Ȱ: ٻڽ ö Ƽա ӻ ͸ 庸 . ȸ(ESMO 2020) ̾ ASCO Ἶ ϰ ִ 3 EGFR ƼνŰ(TKI) Ƽա ׾ü ƹ̹Ÿӻ ͸ ǥϼ̽ϴ. ESMO 2021 ù ǥ پ ȭ ƾ. ش ESMO 2020 ȸ ǥ 7 ߰ Ͱ ƴµ, 'Ÿ׸' ϴ ȯڿ '' 'ƹ̹Ÿ' 36% ƾ.

ûڵ ظ Բ ̹ Ͱ ӻ  ǹ̸ ֽø ϴ.

ö: , ̹ ASCO 2021 Ұ ʹ ESMO 2020 ǥƴ CHRYSALIS 1bӻ󺸴 ٰ ֽϴ. ۳ ǥ Ͱ 4 ̹ ʹ follow up Ⱓ 1 ˴ϴ. Ƽա ƹ̹Ÿ ϴ ȯڵ ϱ ̿Ŀ(üǥ) м ߰.

⼭ ָؾ ģ ڿ 36% ƴٴ ̴ϴ. EGFR MET ̰ Ȯε ȯڵ Ⱓ, ӱⰣ Ҵµ, EGFR MET ̰ ƴ ȯڵ鵵 Ƽա ƹ̹Ÿ 20% ٴ λԴϴ. EGFR MET ̰ Ƽա ƹ̹Ÿ ̿Ŀμ 뼺 ٰ ٴ . ɼ(predictability) ̿Ŀ Ϸ ̿Ŀ 缺 ο ̰ Ŀ մϴ.

̿Ŀ ſ 0% . ̿Ŀ ã ƽ, EGFR MET ̸ ȯڿ Ƽա ƹ̹Ÿ ִٴ ߰ ͸ε ǹ̰ Ůϴ. ̿Ŀ, Ÿ׸ҡ δٴ ߿մϴ.

̹ ASCO 2021мȸ 'Ƽա ƹ̹Ÿ ϴ ȯڸ ִ ̿Ŀ Ȱ ɼ ĺ ִ ƽϴ. 鿪ȭа˻(IHC) 뿰⼭м(NGS) ս ִ ˻ε, IHC EGFR MET ̿ Hھ Ÿ ȯ 10 9(90%) Ÿ½ϴ. ȯڸ м . CHRYSALIS-2 ȣƮD ̿Ŀμ 뼺 Դϴ.

Ȱ: ̿Ŀ ȯ 10 4÷ Ƽա ƹ̹Ÿ ġῡ ٴ ų׿. Բ ̶ 򰡸 ̴ּµ. ̹ Ϳ 纼 ȭ ɼ Ͻó?

ö: ߰ ޹ħž ϱ ȭ ܰ ð ʿմϴ. 㰡 ռ ̱ǰǾ౹(FDA) ȹġ(Breakthrough therapy designation) żӽɻ(fast track designation) ޴ ž ϰ.

CHRYSALIS-2 ̴ϴ. Ÿ׸ҡ ϴ ܼ ݱ ׾ȭп ϰ Ҽ ȯڰ ε, ̷ ȯڵ ̻ ִ ϴ. ̻ ġ ȯڸ CHRYSALIS-1 (36%) ϱ . ȿ ´ٸ FDA ȹġ żӽɻ ޱ⿡ ϴٰ Ǵմϴ. ̳ ʾ ʿ 뷫 ϰ ֽϴ.

Ȱ: , 밡 ˴ϴ. ƽƮī 3 EGFR-TKI Ÿ׸ҡ Ȱϰ óǰ ִµ, ġɼ ٺ 忡 ô. Ÿ׸ҡ غϱ õ پϰ ִ ϴ. ASCO 2021 ͵ µ, EGFR ̰ ƽþ ߻ ٰ ˷ ʾҽϱ. ߱ ̿鵵 EGFR žళ߿ ̴ . ٱ 鵵 ƽþ ӻ Ȱϰ ϴ ϴ.

̹ ȸ Ⱓ EQRx ߱ ׼κ 3 EGFR-TKI 'Ƽ'(aumolertinib) ؼ ο Ͱ ټ ǥǾ. ߱ 簡 ž ۷ι ̿ EQRx ߴµ, Ÿ׸ҡ Ǹϰڴٴ ̷Ӱ ϴ. EQRx ó 'Ƽ' ı ͸ Ŷ Ҵµ, ټ Ǵ κ ôٰ?

ö: ȴٱ ٴ IJϰ 鿩ٺ ʿ䰡 ִ Ͷ . Ƽա ׼ 3 EGFR-TKI 迭 žԴϴ. ƽƮī Ÿ׸ҡ, Ѿ ڡ . Ƽա ƽƮī 1 EGFR ƼνŰ(TKI) '̷'(и Ƽ) ù ° 3 ӻ(RCT) ƴµ, 'Ƽ' ȯ Ⱓ(PFS) ߾Ӱ 19.3, '̷' ϰ Ǹ鼭 ӻ Ÿ½ϴ. 忡 ٸ ׷ ʹ ƴϿ. 3 EGFR-TKI 迭 ๰μ Ÿ׸ҡ ȿ̳ ̶ ߾ŵ.

׷ ؾ ֽϴ. ۷ι ӻ ƴ϶ ߱θ ӻ ߴٴ κε. װ EGFR-TKI ӻͿ 纼 , ȭ ҷ ۿ ̶ ذ ϴ. Ư ̱ FDA ߱θ ӻ Ǹ㰡 ǹ . ڡ ѱ ӻ Ѵٸ ̹ ȯڵ ſ. ׷ ۷ι ӻ ϴ ̰ װ ƴ϶ Ϸ . ۷ι ӻ ӻ󺸴 ޴ Դϴ.

° 鵵 IJϰ ϴ. ̹ ͸ 캸 , , ۷κ ġ ҿ ũƼ Ű(CPK) ġ ˻ ̻Ұ Ÿŵ. Ƽ ̷硯 ̷ ̻ ̰ Ͼ ǹ ۿ . EGFR-TKI ʰŵ. Ѱ 帮 κ 29% Ǵ ƿ(cut off) , īö-̾  (Kaplan-Meier survival curve) 캸 üⰣ(OS) ̰ ״ Ȯ ʴ´ٴ ̴ϴ. ƽƮī Ÿ׸' FLAURA ۷ι 3ӻ ʹ ܰӿ  ̰ ε巯 ŵ. Ƹ FLAURA ӻ󿡴 40% ǰ, Ƽա AENEAS ӻ 0% ɷ Ǵµ. OS ͸ ܺ ̴ϴ.

Ȱ: EQRx ̹ 3ӻ ͸ ٰŷ FDA Ǹ Ѵٰ µ, FDA Ǹ㰡 ϱ ھ. FDA  Ǵ ñ ׿. ڡ͡ƹ̹Ÿ ӻ ٴ ϴ.
޿ Ἶ ƹ̹Ÿ 극Ʈ(Rybrevant) ǰ FDA 㰡 鼭 ڡ ߿ Ǿ ʾҽϱ?

̹ FDA 㰡 극Ʈ Բ һϽ ̶ . Ϻ ϼͿ ӻ 1ӻ ϼ̴ٰ?

ö: ׷ϴ. ִ , ȫ Բ ƹ̹Ÿ(ǰ 극Ʈ)̶ žళ߿ ȹ ߴ ǹִ ְ Ǿ ϴٰ մϴ. ƹ̹Ÿ EGFR cMET ÿ Ÿϴ ׾üԴϴ. ø ص ׾ü ַ ׾ о߿ ̴ ̾, ġо߿ ̾ŵ. ݵ ʽϴ.

ó Ἶ ѱ ϴ ӻ(first-in-human trial) ص  Ȳ̾. EGFR Ŭü ߰ŵ, ΰξϰ Ͽ ̱. MET Ŭü EGFR-TKI 뿬 ٸ . EGFR MET ߿ Ÿ̶ ü Ϸ õ µ, Ἶ ڱ 2 ׾ü ϰڴٰ ſ. ׶ ص ٵ Ǿ. 1ӻ ڵ ޾ҽϴ. ٸ ġḦ ޴ٰ Ϻ ȯڰ EGFR 20 ҰΡƹ̹Ÿ ޾Ҵµ, ƽ Ÿϴ. ʷ ƹ̹Ÿ ȯڰ 20 Ѵ ӱⰣ ſ. ȯڷ Ŭ ġ(clinic to bench) ̷ ſ.

Ϻ ϼͿ ƹ̹Ÿ  EGFR 20 Ͽ Ÿ ִ ľϱ ߰ ߽ϴ. EGFR 20 ̸ 콺 ȯ, ƹ̹Ÿ ϼ ȿ Ȯ. ش ̸ ȯڿԼ ׾ȿ Ȯϸ鼭 ɼ ޾ҽϴ. ش ̱ȸ(AACR) ߰ϴ м ĵĿ(Cancer Discovery) ư. ִ , ȫ ڵ ؼ 81 ȯڸ ۷ι ӻ ư, ͸ 5 FDA  ̴ϴ.

Ȱ: ʱ ܰ迡 ׷ ־⿡ ƹ̹Ÿ 극Ʈ ǰ FDA 㰡 ް ڡ ߵ ź ־ ϴٵ ΰ ޹ħƴٴ λ̳׿.

ڡ CHRYSALIS ǹ̿ ߰ ̾߱ ð. ȫ , ԰ Բ 2 ̾ ٵ, Բ 2 ¦ ֽDz. EGFR ǥ׾ о߿ ߰ Ұֽ ?

ö: ׷ϴ. ̹ ƹ̹Ÿ 㰡 EGFR 20 ̷ο ͵ . EGFR 20 ̴ ü EGFR 12% Ѵٴ մϴ. ƹ̹Ÿó ü ƴ϶ ҺǾǰ ġ õǰ ְ, ASCO 2021 ɴ 𺸼Ƽ(mobocertinib), ߱ ĸ DZD9008, ø CLN-081 3 žĺ Ͱ Ұƽϴ. ݱ δ 3 ๰ ټ ̰ ȿ 鿡 ϴٰ Ǵܵ˴ϴ.

׹ۿ Ÿ׸ҡ ̸ غϱ õμ 찡 HER3 ǥ ü๰ü(ADC) Ʈ(Patritumab deruxtecan) ๰ ϴ.

Ȱ: , ð̾ϴ. 2ο ȫ ԰ Բ ASCO 2021 ǥ 鿪 ǥ׾ о ̷ο ͸ 캸 ð մϴ. 2ε ּ. ٻڽ ڸ ֽ Բ ٽ ѹ 帳ϴ.

'ASCO 2021' -2 ּ.
Ȱ (kjan@dailypharm.com) ٸ
  • μ
  • īī
  • ̽
  • Ʈ
  • 1
ñ
/home/dailypharm/issueData2017/
ǰ
1
͸ǰ | Ǹǰ߾ Ģ
ݱ

Ǹ ͸ , Ǹ ̸ ̵ ˴ϴ. ͸ ʸ ϸ, ͸ մϴ.

ڹ(-ڴϾ-ʱ ) ˵ ϸ ȸ Խ ⡯ ĺ Ʈ ׻ ֻܿ ˴ϴ. ο ø Ϲȸ Խ ĺ ڴϾ ȸ ϴܿ ǽð ˴ϴ.

뺸 ϰ ̵ ̿ Ǵ ֽϴ.

  • ۱ǡΰݱ Ÿ Ǹ ħϴ

    α׷ ϰ , ȳϴ Խù

    Ÿ Ǵ 3 ۱ Ÿ Ǹ ħ Խù

  • ٰ 桤 Ѽϴ Խù

    Ư ̿ ο ν 弳

    Ư 븳 ϴ

    Ȯ ȵ ҹ Ű

    弳 , Ӿ

    Ź, ɿ ˵Ǵ ( û )

    Ư ̳ ü ϴ

    Ư ѼϿ ش ûϴ

    Ư (ֹεϹȣ, ȭ, ּ ) Խϴ

    Ÿ ID Ȥ г ϴ

  • Խ Ư ѵǴ

    ʴ

    翡 ߺ

    κ Ͽ ݺ ϴ 쵵

    Խù,

    Ե Խù

    Խù б

  • û ִ

  • Ÿ

    ʿ伺 ̸

    Ÿ ˵Ǵ 縦

    Ÿ  ڰ ʿϴٰ ǴܵǴ

  • Ȯ

    ۱ڷκ , , ϴ

    Ÿ ʻ ħϰų ϴ

    翡 ̿ (Ÿ ID, йȣ )

  • ̻ Ϻ ׿ ̿ 縦 , Ρ ó ֽϴ.

    õ ̴ ҹ Ǵܵǰų ϸ 񽺿 ٶ ʴٰ ǴܵǴ ġ ϰڽϴ.

    رŸ ϸ ڿ ֽʽÿ. ּҴ dailypharm@dailypharm.comԴϴ.

ֽż ݴ
  • 2021.06.24 11:25:36 |

    ö̿ܿ Ծ

    0 3 3
౹ Ϲݾ Top 100(03)
ǰ Ƚ Ǹűݾ
1 Ÿ̷500mg(10) 23638 33104 101,505,000
2 Ȱť 13391 83427 97,389,700
3 Ǹť 10902 91595 73,069,159
4 ݿ 11997 88325 71,846,700
5 ũũ 4431 4720 52,151,000
6 뽺ī 20g 2332 2418 49,544,700
7 319 12291 44,946,300
8 Ź ĸ(10ĸ) 10732 15961 42,562,800
9 S 676 1227 42,429,350
10 ݴ ť÷ 8546 11210 42,423,060
11 ̰źĸ(60ĸ) 1292 2602 37,202,100
12 ġ 8140 41776 36,792,300
13 öŸ(34) 2501 3833 35,705,600
14 ׶÷ ƮŸ 3353 4312 35,035,660
15 Ʒγΰ̾(120) 657 810 34,246,900
16 ġ̽Ʈġ120g 2388 3282 34,107,490
17 öŸ(40) 2100 2586 34,093,300
18 ٿ 30g 2899 5594 33,943,700
19 (120) 1218 2384 32,914,000
20 ڶ-(40) 1737 3804 28,306,900
21 Ժ 5110 8423 27,914,600
22 Ź 3783 5019 27,081,000
23 ƽŸ 434 825 26,872,500
24 ׶÷ ݵ& Ʈ 1824 2172 25,848,300
25 (10) 8429 12233 25,619,101
26 ȲûɿŹ50ml(õ) 1192 2335 25,361,000
27 ݴ ݵť÷ 5324 6920 25,224,900
28 Ÿ̷500mg(30) 2468 3258 24,699,390
29 Ľõ򿬰10׶ 3091 3369 24,306,500
30 6089 25744 24,196,461
31 Ʒ 3226 7806 24,186,252
32 6̺(30ĸ) 2737 3245 23,701,750
33 ġ̽Ʈġ150g 1401 1754 23,469,900
34 ũ 1907 1963 23,302,401
35 λ絹÷(100) 671 1981 22,752,400
36 ݿ 5552 7933 22,665,600
37 ťýȾ0.5ml*60 1158 1319 22,004,000
38 D-׳ 2074 2207 21,799,902
39 Ľõ򿬰5g 3700 3954 20,580,200
40 뽺ī 10g 1603 1663 20,406,600
41 ӽ÷ 1879 2250 20,176,000
42 öŸ 3232 7567 19,371,321
43 ȲûɿŹ50ml() 1585 3803 19,128,000
44 Ȳûɿȯ() 255 1579 19,058,500
45 ƽƮ(150) 195 351 18,535,100
46 Ÿ̷8ð̾˼ 4493 6574 18,407,000
47 ʽ÷÷ 2748 3217 18,376,001
48 īɾ10g 2552 2817 18,221,600
49 Ʒγΰ(100) 525 1187 18,136,800
50 (10) 2814 3718 18,035,700
51 6̺꿬ĸ(10ĸ) 4711 6546 17,234,600
52 ھ ߽20ml 1500 1754 17,208,900
53 ƽŸ 313 594 16,459,972
54 ݴŰ÷ 3393 4385 15,960,800
55 ̵Ⱦ 14ml 2463 2769 15,949,650
56 ǥȲûɿ 50ml 1061 3758 15,544,646
57 ڷƮ 2mg (Ʈ) 693 1630 15,516,200
58 Ź 2643 3839 15,388,600
59 ѺŸC1000mg 814 2828 15,249,703
60 λ絹÷(270) 194 737 15,225,500
61 밢()(18) 1795 2220 15,094,100
62 ̵Ⱦ 14ml 2416 2576 14,910,600
63 λ絹(100) 491 907 14,826,800
64 ׺ƽĸ 294 546 14,789,500
65 翬ĸ(120ĸ) 372 387 14,722,300
66 Ź̵ 3100 3837 14,720,200
67 Ʈ0.1%й 1182 1495 14,673,700
68 ȭ 4074 18105 14,639,465
69 Ʒ 2856 4634 14,629,300
70 ѽŻ÷(10) 3458 5196 14,582,200
71 ׺ǵ 1246 7135 14,399,712
72 ݴŰ÷ 3107 3696 14,384,750
73 ÷ 3969 4682 14,254,868
74 ƼǪīŸö󽺸 2531 4745 13,924,700
75 ̵Ⱦ׼ 14ml 2151 2411 13,871,800
76 īٿĸ(60ĸ) 299 427 13,498,500
77 ΰ 155 206 13,325,000
78 2480 9352 13,106,010
79 ξ 487 5011 13,096,210
80 ƼǪ Ŀ 1714 3762 13,033,911
81 īɾ 6g 2647 2864 12,758,350
82 10 1610 2720 12,753,338
83 ƽúŰ÷(10) 2340 2566 12,706,610
84 ġĸ(60ĸ) 452 984 12,697,600
85 տ翬ĸ(80ĸ) 349 449 12,559,600
86 Ǫ÷ 3092 4079 12,536,300
87 īڿ;(300) 425 459 12,408,600
88 Ÿ̷ݵ忡 2519 3686 12,349,800
89 2% 120ml 683 707 12,166,600
90 ġĸ(120ĸ) 241 251 12,094,000
91 ȯ 1945 2815 12,000,300
92 Ŭƾ 972 1013 11,992,500
93 ƼǪ Ŀ 1949 4686 11,989,100
94 ݴ ť÷ 2523 3104 11,948,900
95 ǥȲûɿ50ml(õ⺯) 584 1190 11,875,100
96 1100 1463 11,805,800
97 ؽ 1141 1198 11,802,000
98 ڸŰĸ 2134 2516 11,677,500
99 Ⱦ0.5ml 573 659 11,636,000
100 ƮƮŰ& 1615 2330 11,516,140
ü



ͳݽŹϹȣ: 00048 | 2005.09.09 | 2005.09.09 | : | : ȣ
ּ: ı 128 SK V1 GL ƮνƼ A 401ȣ
ȭ : 02-3473-0833 |ѽ : 02-3474-0169 | ûҳ⺸ȣå(å ű)
Contact dailypharm@dailypharm.com for more information
ϸ () ϴ ۱ǹ ˵Ǹ, 縦 ֽϴ.